87 related articles for article (PubMed ID: 17909087)
1. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose.
Utzschneider KM; Tong J; Montgomery B; Udayasankar J; Gerchman F; Marcovina SM; Watson CE; Ligueros-Saylan MA; Foley JE; Holst JJ; Deacon CF; Kahn SE
Diabetes Care; 2008 Jan; 31(1):108-13. PubMed ID: 17909087
[TBL] [Abstract][Full Text] [Related]
2. Sitagliptin improves glycaemic excursion after a meal or after an oral glucose load in Japanese subjects with impaired glucose tolerance.
Kaku K; Kadowaki T; Terauchi Y; Okamoto T; Sato A; Okuyama K; Arjona Ferreira JC; Goldstein BJ
Diabetes Obes Metab; 2015 Nov; 17(11):1033-41. PubMed ID: 26094974
[TBL] [Abstract][Full Text] [Related]
3. Chitosan oligosaccharide (GO2KA1) improves postprandial glycemic response in subjects with impaired glucose tolerance and impaired fasting glucose and in healthy subjects: a crossover, randomized controlled trial.
Jeong S; Min Cho J; Kwon YI; Kim SC; Yeob Shin D; Ho Lee J
Nutr Diabetes; 2019 Nov; 9(1):31. PubMed ID: 31685797
[TBL] [Abstract][Full Text] [Related]
4. Ginseng and ginsenoside Re do not improve β-cell function or insulin sensitivity in overweight and obese subjects with impaired glucose tolerance or diabetes.
Reeds DN; Patterson BW; Okunade A; Holloszy JO; Polonsky KS; Klein S
Diabetes Care; 2011 May; 34(5):1071-6. PubMed ID: 21411505
[TBL] [Abstract][Full Text] [Related]
5. Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial.
Kothny W; Lukashevich V; Foley JE; Rendell MS; Schweizer A
Diabetologia; 2015 Sep; 58(9):2020-6. PubMed ID: 26067186
[TBL] [Abstract][Full Text] [Related]
6. Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study.
Matthews DR; Dejager S; Ahren B; Fonseca V; Ferrannini E; Couturier A; Foley JE; Zinman B
Diabetes Obes Metab; 2010 Sep; 12(9):780-9. PubMed ID: 20649630
[TBL] [Abstract][Full Text] [Related]
7. The effect of DPP-4 inhibition with sitagliptin on incretin secretion and on fasting and postprandial glucose turnover in subjects with impaired fasting glucose.
Bock G; Dalla Man C; Micheletto F; Basu R; Giesler PD; Laugen J; Deacon CF; Holst JJ; Toffolo G; Cobelli C; Rizza RA; Vella A
Clin Endocrinol (Oxf); 2010 Aug; 73(2):189-96. PubMed ID: 20039889
[TBL] [Abstract][Full Text] [Related]
8. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance.
Rosenstock J; Foley JE; Rendell M; Landin-Olsson M; Holst JJ; Deacon CF; Rochotte E; Baron MA
Diabetes Care; 2008 Jan; 31(1):30-5. PubMed ID: 17947341
[TBL] [Abstract][Full Text] [Related]
9. Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial.
McMurray JJV; Ponikowski P; Bolli GB; Lukashevich V; Kozlovski P; Kothny W; Lewsey JD; Krum H;
JACC Heart Fail; 2018 Jan; 6(1):8-17. PubMed ID: 29032139
[TBL] [Abstract][Full Text] [Related]
10. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial.
Matthews DR; Paldánius PM; Proot P; Chiang Y; Stumvoll M; Del Prato S;
Lancet; 2019 Oct; 394(10208):1519-1529. PubMed ID: 31542292
[TBL] [Abstract][Full Text] [Related]
11. Initial combination therapy with vildagliptin plus metformin in drug-naïve patients with T2DM: a 24-week real-life study from Asia.
Chawla M; Kim TH; Mirasol RC; Faruque P; Cooke K; Hours-Zesiger P; Shete A
Curr Med Res Opin; 2018 Sep; 34(9):1605-1611. PubMed ID: 29764225
[TBL] [Abstract][Full Text] [Related]
12. Effects of Vildagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on the Parameters of Glucose Metabolism and the Cardio-Ankle Vascular Index in Individuals with Type 2 Diabetes.
Nagayama D; Kawana H; Watanabe Y; Horikawa O; Ohira M; Saiki A
J Clin Med; 2024 Jan; 13(2):. PubMed ID: 38256615
[TBL] [Abstract][Full Text] [Related]
13. Beta-cell function in type 2 diabetes (T2DM): Can it be preserved or enhanced?
Sayyed Kassem L; Rajpal A; Barreiro MV; Ismail-Beigi F
J Diabetes; 2023 Oct; 15(10):817-837. PubMed ID: 37522521
[TBL] [Abstract][Full Text] [Related]
14. Diabetes in Kidney Transplantation.
Martinez Cantarin MP
Adv Chronic Kidney Dis; 2021 Nov; 28(6):596-605. PubMed ID: 35367028
[TBL] [Abstract][Full Text] [Related]
15. Berberine Slows the Progression of Prediabetes to Diabetes in Zucker Diabetic Fatty Rats by Enhancing Intestinal Secretion of Glucagon-Like Peptide-2 and Improving the Gut Microbiota.
Wang Y; Liu H; Zheng M; Yang Y; Ren H; Kong Y; Wang S; Wang J; Jiang Y; Yang J; Shan C
Front Endocrinol (Lausanne); 2021; 12():609134. PubMed ID: 34025574
[TBL] [Abstract][Full Text] [Related]
16. Small changes in glucose variability induced by low and high glycemic index diets are not associated with changes in β-cell function in adults with pre-diabetes.
Utzschneider KM; Johnson TN; Breymeyer KL; Bettcher L; Raftery D; Newton KM; Neuhouser ML
J Diabetes Complications; 2020 Aug; 34(8):107586. PubMed ID: 32546421
[TBL] [Abstract][Full Text] [Related]
17. Effects of Dapagliflozin and Sitagliptin on Insulin Resistant and Body Fat Distribution in Newly Diagnosed Type 2 Diabetic Patients.
Sun Y; Yan D; Hao Z; Cui L; Li G
Med Sci Monit; 2020 Apr; 26():e921891. PubMed ID: 32240122
[TBL] [Abstract][Full Text] [Related]
18. Insights Into GLP-1 and GIP Actions Emerging From Vildagliptin Mechanism Studies in Man.
Foley JE
Front Endocrinol (Lausanne); 2019; 10():780. PubMed ID: 31781045
[TBL] [Abstract][Full Text] [Related]
19. Effect of sitagliptin on energy metabolism and brown adipose tissue in overweight individuals with prediabetes: a randomised placebo-controlled trial.
Nahon KJ; Doornink F; Straat ME; Botani K; Martinez-Tellez B; Abreu-Vieira G; van Klinken JB; Voortman GJ; Friesema ECH; Ruiz JR; van Velden FHP; de Geus-Oei LF; Smit F; Pereira Arias-Bouda LM; Berbée JFP; Jazet IM; Boon MR; Rensen PCN
Diabetologia; 2018 Nov; 61(11):2386-2397. PubMed ID: 30145664
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
